Tan Li

Founder en SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. .

Fortuna: 471 M $ al 31/03/2024

60 años

100 relaciones

Health Technology

Consumer Services

Distribution Services

Perfil

Tan Li fundó Shenzhen Hepalink Pharmaceutical Group Co. Ltd. La Sra. Li es directora ejecutiva y subdirectora general de esta empresa y socia ejecutiva de Urumqi Jintiantu Equity Investment Partnership LP. La Sra. Li también forma parte del consejo de administración de Kymab Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. y Kymab Group Ltd. Se licenció en la Universidad de Sichuan.

Participaciones conocidas en empresas públicas

Empresa	Fecha	Número de acciones	Valoración	Fecha de valoración
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. CLASS A 32.72%	30/06/2023	408 041 280 ( 32.72% )	471 M $	31/03/2024

Cargos activos de Tan Li

Empresas	Cargo	Inicio
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.	Founder	21/04/1998
Urumqi Jintiantu Equity Investment Partnership LP	Corporate Officer/Principal	09/08/2013
Shenzhen Techdow Pharmaceutical Co., Ltd.	Director/Board Member	-
Shenzhen Duopule Industrial Development Co., Ltd. Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million.	Director/Board Member	13/01/2014
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Director/Board Member	-
Kymab Group Ltd. Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.	Director/Board Member	20/01/2017

Todos los cargos activos de Tan Li

Formación de Tan Li.

Sichuan University

Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Tan Li.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.	Health Technology

Empresas privadas	5
Urumqi Jintiantu Equity Investment Partnership LP
Kymab Ltd. Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.	Health Technology
Shenzhen Techdow Pharmaceutical Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million.	Distribution Services
Kymab Group Ltd. Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.	Health Technology

Ver las conexiones de la empresa